Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Inovio Pharmaceuticals ( (INO) ).
On May 19, 2026, Inovio Pharmaceuticals amended its bylaws to refine its corporate governance framework, clarifying that the chairman of the board is not automatically an officer, formalizing the role and responsibilities of a lead independent director, and revising the order of presiding officers at board and stockholder meetings. These changes are designed to strengthen board independence and oversight, particularly in situations where the chief executive also serves as chairman.
At the May 20, 2026 annual meeting, shareholders elected eight directors to serve until the 2027 meeting and ratified Ernst & Young LLP as the company’s independent auditor for the 2026 fiscal year. Investors also approved, on an advisory basis, executive compensation and backed an amended and restated 2023 omnibus incentive plan, signaling broad support for Inovio’s leadership, governance adjustments and long-term incentive structures.
The most recent analyst rating on (INO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Inovio Pharmaceuticals stock, see the INO Stock Forecast page.
Spark’s Take on INO Stock
According to Spark, TipRanks’ AI Analyst, INO is a Neutral.
Overall score reflects very weak financial performance (minimal revenue, heavy losses, sustained cash burn and increased leverage risk) as the primary drag. The earnings call adds moderate upside due to regulatory milestones and encouraging Phase I/II signals, but near-term liquidity needs and remaining FDA uncertainty temper that. Technicals are neutral-to-mixed and valuation offers limited support due to ongoing losses.
To see Spark’s full report on INO stock, click here.
More about Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA-based medicines, with operations centered on researching and advancing novel therapeutics for serious diseases. The company’s governance structure includes a board of directors and committees overseeing areas such as audit, executive compensation and broader corporate oversight, reflecting its role as a publicly traded life sciences issuer.
Average Trading Volume: 2,496,666
Technical Sentiment Signal: Sell
Current Market Cap: $99.96M
See more data about INO stock on TipRanks’ Stock Analysis page.